Economic Issues and Viability of Gene-Based Molecular Therapies for Cardiovascular Disease
Abstract
Gene-based molecular therapies (GMTs) have the potential to transform cardiovascular care through single-administration interventions with durable or curative effects. While RNA-based therapies such as inclisiran are already approved for lipid lowering, no in vivo gene addition or gene editing therapy has yet received approval for a primary cardiovascular indication. As these therapies approach clinical readiness, their adoption will be shaped less by scientific feasibility than by economic viability. This commentary examines the key economic barriers to pricing, reimbursement, and adoption of cardiovascular GMTs, and reviews emerging payment models aimed at aligning cost with long-term therapeutic value.
Fields of Study & Subjects
Pharmaceutical Economics and Policy
Health Systems
Economic Evaluations
Quality of Life
Virus-based gene therapy research
Publication details
- Journal / source
- Canadian Journal of Cardiology
- Volume
- 42
- Issue
- 5
- Pages
- 1047–1050
- Publication date
- 7 March 2026
- Language
- EN